Interpretive reading of the antibiogram of enterobacteria;Lectura interpretada del antibiograma de enterobacterias

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 20, Issue 5, 2002, Pages 225-234

  Navarro Risueño, Ferran ^a   Miró Cardona, Elisenda ^b   Mirelis Otero, Beatriz ^b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b NONE

Author keywords

Determination of sensitivity; Enterobacteria; Resistance

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFALOTIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CHLORAMPHENICOL; CILASTATIN PLUS IMIPENEM; COLISTIN; COTRIMOXAZOLE; FOSFOMYCIN; KANAMYCIN; NALIDIXIC ACID; NETILMICIN; NITROFURANTOIN; NORFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; SULFONAMIDE; TETRACYCLINE; TICARCILLIN; TIMENTIN; TOBRAMYCIN; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ENTEROBACTERIACEAE; ENZYME SYNTHESIS; GENE MUTATION; PHENOTYPE;

EID: 0036275933     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0213-005X(02)72796-1     Document Type: Article

References (38)

1. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-51.
2. Cantón R. Lectura interpretada del antibiograma: ¿ejercicio intelectual o necesidad clínica? Enferm Infecc Microbiol Clin 2002 (en prensa).
3. Thomson KS. Controversies about extended-spectrum and AmpC beta-lactamases. Emerg Infect Dis 2001;7:333-6.
4. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing; Eleventh Informational Supplement. NCCLS Document M100-S11. Wayne, 2001.
5. Comité de l'Antibiogramme de la Société Francaise de Microbiologie. Communique 2000-2001. 2001. Disponible en: http://www.sfm.asso.fr/Sect4/ com2001.pdf.
6. García Rodríguez JA, Cantón R, García Sánchez JE, Gómez-Lus ML, Martínez-Martínez L, Rodríguez-Avial C, et al. 11. Métodos básicos para el estudio de la sensibilidad a los antimicrobianos. En: Picazo JJ, ed. Procedimientos en Microbiología Clínica. Disponible en: http://www.seimc.org/.
7. Miró E, Alonso C, Navarro F, Mirelis B, Prats G. Resistencia al imipenem en Enterobacter aerogenes. Enferm Infecc Microbiol Clin 1995;13:278-82.
8. Stapleton PD, Shannon KP, French GL. Carbapenem resistance in Escherichia coli associated with plasmid-determined CMY-4 β-lactaraase production and loss of an outer membrane protein. Antimicrob Agents Chemother 1999;43:1206-10.
9. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the loss of an outer membrane protein. Antimicrob Agents Chemother 1997;41:563-9.
10. Nikaido H. Outer membrane barrier as a mechanism of antimicrobial resistance. Antimicrob Agents Chemother 1989;33:1831-6.
11. Livermore DM, Winstanley TG, Shannon KP. Interpretative reading: Recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. J Antimicrob Chemother 2001;48(Suppl)S1:87-102.
12. Livermore DM. β-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-84.
13. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33.
14. García Rodríguez JA, Cantón R, García Sánchez JE, Gómez-Lus ML, Martínez-Martínez L, Rodríguez-Avial C, et al. 12. Métodos especiales para el estudio de la sensibilidad a los antimicrobianos. En: Picazo JJ, ed. Procedimientos en Microbiologia Clinica. Disponible en: http://www.seimc.org/.
15. Pham JN, Bell SM, Martin L, Carniel E. The β-lactamases and β-lactam antibiotic susceptibility of Yersinia enterocolitica. J Antimicrob Chemother 2000;46:951-7.
16. Fournier B, Lu CY, Lagrange PH, Krishnamoorthy R, Philippon A. Point mutation in the pribnow box, the molecular basis of β-lactamase overproduction in Klebsiella oxytoca. Antimicrob Agents Chemother 1995;39:1365-8.
17. Nelson EC, Elisha BG. Molecular basis of AmpC hyperproduction in clinical isolates of Escherichia coli. Antimicrob Agents Chemother 1999;43:957-9.
18. Wiedemann B, Dietz H, Pfeifle D. Induction of β-lactamase in Enterobacter cloacae. Clin Infect Dis 1998;27(Suppl 1):42-7.
19. Miró E, Del Cuerpo M, Navarro F, Sabaté M, Mirelis B, Prats G. Emergence of clinical Escherichia coli isolates with decreased susceptibility to ceftazidime and synergic effect with co-amoxiclav due to SHV-1 hyperproduction. J Antimicrob Chemother 1998;42:535-53.
20. Navarro F, Miro E. Update on CTX-M-type β-lactamases. Rev Med Microbiol 2002. En prensa.
21. Prinarakis EE, Miriagou V, Tzelepi E, Gazouli M, Tzouvelekis LS. Emergence of an inhibitor-resistant beta-lactamase (SHV-10) derived from an SHV-5 variant. Antimicrob Agents Chemother 1997;41:838-40.
22. Chaibi EB, Sirot D, Paul G, Labia R. Inhibitor-resistant TEM β-lactamase: Phenotypic, genetic and biochemical characteristics. J Antimicrob Chemother 1999;43:447-58.
23. Philippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type β-lactamases Antimicrob Agents Chemother 2002;46:1-11.
24. Livermore DM. Acquired carbapenemases. J Antimicrob Chemother 1997; 39:673-6.
25. Prats G, Miro E, Mirelis B, Poirel L, Bellais S, Nordmann P. First isolation of carbapenen-hydrolyzing β-lactamases in Pseudomonas aeruginosa, in Spain. Antimicrob Agents Chemother 2002;46:932-3.
26. Lemozy J, Bismuth R, Courvalin P. Enterobacteries et aminosides. En: Courvalin P, Goldstein F, Philippon A, Sirot J, eds. L'Antibiogramme. Bruselas: MPC 1985;111-25.
27. Shaw KJ, Rather PN, Hare RS, Miller GH. Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev 1993;57:138-63.
28. Chiew YF, Yeo SF, Hall LMC, Livermore DM. Can susceptibility to an antimicrobial be restored by halting its use? The case of streptomycin versus Enterobacteriaceae. J Antimicrob Chemother 1998;41:247-51.
29. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new "respiratory quinolones". J Antimicrob Chemother 1999;43(Suppl B):1-11.
30. Hooper DC. Bacterial topoisomerascs, anti-topoisomerases, and anti-topoisomerase resistance. Clin Infect Dis 1998;27(Suppl 1):54-63.
31. Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998;351:797-9.
32. Oethinger M, Kern WV, Jellen-Ritter AS, McMurry LM, Levy SB. Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump. Antimicrob Agents Chemother 2000;44:10-3.
33. Fluit ADC, Visser MR, Schmitz FJ. Molecular detection of antimicrobial resistance. Clin Microbiol Rev 2001;14:836-71.
34. Vila J, Ruiz J, Marco F, Barcelo A, Goni PE, Giralt E, et al. Association between double mutation in the gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob Agents Chemother 1994;38: 2477-9.
35. Wain J, Hoa NT, Chinh NT, Vinh H, Everett MJ, Diep TS, et al. Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment. Clin Infect Dis 1997;25:1404-10.
36. Vasallo FJ, Martín Rabadán P, Alcalá L, Garcia-Lechuz JM, Rodríguez-Creixems, Bouza E. Failure of ciprofloxacin therapy for invasive nontyphoidal salmonellosis. Clin Infect Dis 1998;26:535-6.
37. Sabate M, Miro E, Navarro F, Verges C, Aliaga R, Mirelis B, et al. β-lactamases involved in resistance to broad-spectrum cephalosporins in Escherichia coli and Klebsiella spp. clinical isolates between 1994-1996 in (Barcelona) Spain. J Antimicrob Chemother 2002. En prensa.
38. Navarro F, Perez-Trallero E, Marimon JM, Aliaga R, Gomariz M, Mirelis B. CMY-2-producing Salmonella enterica, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis and Escherichia coli strains isolated in Spain (October 1999-December 2000). J Antimicrob Chemother 2001;48:383-389.